Among the nine genes, UBE2B inhibitor TZ9 was accessible, two myeloma cell lines (MM.1S, H929) were treated with a range dose of TZ9 for 48 h, cell viability was significantly reduced and analyzed by CCK8 assay, and H929 was more sensitive to TZ9 with IC50 was 7.757 μM (Figure 8D). Here, UBE2B is linked to plasma cell myeloma.